Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function

Lanzhou Li, Chenfei Zhao, Fange Kong, Yicong Li, Chunxia Wang, Shanshan Chen, Hor‐Yue Tan, Yang Liu, Di WangFrontiers in Pharmacology 2022 · DOI

TL;DR

This study investigates Calf Thymus Polypeptide (CTP) as a potential treatment for colorectal cancer (CRC). Researchers found that CTP effectively suppressed tumor growth in mice by modulating the gut microbiome and enhancing the immune system's anti-cancer activity, particularly by boosting T cell and NK cell function.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant global health burden, ranking as the fourth most common cancer and the third leading cause of cancer-related deaths worldwide. While standard treatments like surgery, chemotherapy, and radiotherapy exist, they often have limitations, including incomplete eradication of cancer cells and local recurrence. There's a continuous need for novel, safe, and effective therapeutic strategies. This paper addresses the challenge of finding such alternatives by exploring the potential of CTP, a substance derived from calf thymus, to combat CRC. Specifically, it investigates how CTP might influence the complex interplay between the intestinal microbiota and the host's immune system to achieve its anti-cancer effects.

Methods

The researchers utilized a well-established mouse model for CRC, the Apc<sup>Min/+</sup> mice, which spontaneously develop intestinal tumors due to a mutation in the Adenomatous Polyposis Coli (APC) gene. These mice were treated with CTP at a dose of 6.75 mg/kg daily for 56 days, with a control group receiving a vehicle.

Key techniques employed included:

  • Flow Cytometry: To quantify immune cell populations, specifically Natural Killer (NK) cells (CD3e<sup>-</sup>NK1.1<sup>+</sup>) and activated T cells (CD3e<sup>+</sup>CD28<sup>+</sup>), in the peripheral blood.
  • 16S rRNA Gene Sequencing: To analyze the composition and diversity of the intestinal microbiota in the cecal contents.
  • Enzyme-Linked Immunosorbent Assay (ELISA): To measure the levels of various immune-related cytokines in serum and colorectal tissues.
  • Immunohistochemistry and Western Blot: To assess the expression of key immune proteins (e.g., CD4, CD8, IFN-γ, IL-4, PD-1, PD-L1, CTLA4, NFAT1, NF-κB p65) in spleen and tumor tissues.
  • Histopathological Analysis: To examine the morphological changes in colorectal tumor tissues after CTP treatment.

Datasets

The study used data generated from experiments conducted on Apc<sup>Min/+</sup> mice. The 16S rRNA gene sequencing data from the intestinal microbiota was uploaded to the NCBI Sequence Read Archive with the accession number PRJNA796779. No other external datasets were used for training or evaluation.

Key Insights and Ideas

  • Microbiota Modulation is Key: CTP's anti-cancer effect isn't solely due to direct tumor killing but significantly involves reshaping the gut microbiome. This highlights the growing understanding of the gut-brain-immune axis in disease.
  • Immune System Re-engagement: CTP appears to "wake up" a suppressed immune system in the context of CRC. It boosts the activity of crucial immune cells like NK cells and cytotoxic T cells, which are vital for recognizing and eliminating cancer cells.
  • Shifting the Balance: CTP promotes a shift towards a pro-inflammatory, anti-tumor immune response (Th1-biased) by increasing IFN-γ and IL-2 while decreasing immunosuppressive cytokines like IL-4 and TGF-β.
  • Targeting Immune Checkpoints: The reduction in immune checkpoint proteins like PD-1, PD-L1, and CTLA4 suggests CTP might work synergistically with existing immunotherapies that target these pathways.
  • IL-2 Signaling Pathway Activation: The study points to the IL-2 signaling pathway as a central mechanism through which CTP exerts its immune-modulatory effects, influencing T cell activation and proliferation.

Key Results

  • Tumor Suppression: CTP significantly reduced the number and size of colorectal tumors in Apc<sup>Min/+</sup> mice, leading to a 20.98% decrease in the colorectal index.
  • Immune Cell Enhancement: CTP treatment increased circulating CD3e<sup>-</sup>NK1.1<sup>+</sup> (NK) cells by 113.0% and CD3e<sup>+</sup>CD28<sup>+</sup> (activated T) cells by 84.7% in the peripheral blood.
  • Microbiota Improvement: CTP enhanced the richness, diversity, and evenness of the intestinal microbiota. Specifically, it increased the abundance of beneficial bacteria like Clostridia and decreased harmful bacteria such as Desulfovibrionaceae.
  • Cytokine Regulation: CTP significantly increased pro-inflammatory cytokines like IL-2 (15.19% increment) and IL-12 (17.47% increment) while reducing immunosuppressive TGF-β (11.19% reduction) in serum and/or colorectum.
  • Immune Protein Modulation: CTP increased CD4 and CD8 levels in spleen and tumors, promoted IFN-γ, and suppressed IL-4, indicating a Th1-biased immune response. It also reduced PD-1, PD-L1, and CTLA4 levels.

Limitations and Future Work

The authors acknowledge two main limitations:

  • Detailed Mechanism of Differentiation: While the study confirms CTP's association with T cell activity, the precise mechanisms by which CTP influences T cell differentiation require further investigation.
  • Clinical Translation: The anti-CRC effect of CTP has been confirmed in a preclinical mouse model. Further clinical trials are needed to validate its efficacy and safety in human patients.

The study suggests that CTP could serve as a valuable therapeutic agent or a combination therapy for CRC, providing a foundation for future clinical investigations.

Summary updated

Abstract

Calf thymus polypeptide (CTP), with a molecular mass of <10 kDa, is prepared from the thymus of less than 30-day-old newborn cattle. In the present study, the inhibitory function of CTP in colorectal cancer (CRC) was investigated in B6/JGpt-<i>Apc</i> <sup><i>em1Cin(MinC)</i></sup> /Gpt (<i>Apc</i> <sup>Min/+</sup>) mice. CTP hampered tumor development and enhanced the ratio of CD3e<sup>-</sup>NK1.1<sup>+</sup> cells by 113.0% and CD3e<sup>+</sup>CD28<sup>+</sup> cells by 84.7% in the peripheral blood of <i>Apc</i> <sup>Min/+</sup> mice. CTP improved the richness, diversity, and evenness of the intestinal microbiota of <i>Apc</i> <sup>Min/+</sup> mice, particularly by regulating the abundance of immune-related microorganisms. CTP effectively regulated the expression of immune-related cytokines, such as interleukin (IL)-2 (15.19% increment), IL-12 (17.47% increment), and transforming growth factor (TGF)-β (11.19% reduction). Additionally, it enhanced the levels of CD4 and CD8, as well as the ratio of helper T lymphocytes (Th)1/Th2 in the spleen and tumors of <i>Apc</i> <sup>Min/+</sup> mice. In CTP-treated mice, reduced levels of programmed death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), activated nuclear factor of activated T cells 1 (NFAT1), and nuclear factor κB (NF-κB) p65 signaling were noted. Collectively, the anti-CRC effect of CTP is related to the modulation of intestinal microbiota-mediated immune function, which provides a reference for CTP as a therapeutic drug or a combination drug used in CRC treatment in a clinical setting.
BibTeX
@inproceedings{li2022calf,
  author = {Lanzhou Li and Chenfei Zhao and Fange Kong and Yicong Li and Chunxia Wang and Shanshan Chen and Hor‐Yue Tan and Yang Liu and Di Wang},
  title = {{Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.898906},
}
Figure